VEU - Vanguard FTSE All-Wld ex-US ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
54.89
-0.28 (-0.51%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close55.17
Open54.99
Bid0.00 x 0
Ask0.00 x 0
Day's Range54.77 - 55.02
52 Week Range48.54 - 58.90
Volume1,056,060
Avg. Volume2,862,109
Net Assets38.28B
NAV54.21
PE Ratio (TTM)N/A
Yield2.69%
YTD Return-0.35%
Beta (3y)0.94
Expense Ratio (net)0.11%
Inception Date2007-03-02
Trade prices are not sourced from all markets
  • Analysts’ Recommendations for Novartis on April 17
    Market Realist4 days ago

    Analysts’ Recommendations for Novartis on April 17

    Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16. For 1Q18, analysts expect Novartis to see EPS of $1.28 on revenue of $12.6 billion.

  • How AstraZeneca’s 1Q18 Shook Out
    Market Realist13 days ago

    How AstraZeneca’s 1Q18 Shook Out

    Headquartered in London, AstraZeneca (AZN) is a pharmaceutical company with operations in over 100 countries. The company is involved in the research, development, and manufacture of drugs for both primary care and specialty care.

  • 3 Top Index Funds to Keep You in the Investing Game
    Motley Fool26 days ago

    3 Top Index Funds to Keep You in the Investing Game

    Worried about picking individual stocks? Try out these three index funds.

  • March Madness ETF Prediction and Sweet 16 Picks
    Zackslast month

    March Madness ETF Prediction and Sweet 16 Picks

    The excitement surrounding the tournament and its impact on the stock world has led investors to look at ETFs that could act as a proxy for the game.

  • How Novartis’s Business Segments Performed in 4Q17
    Market Realistlast month

    How Novartis’s Business Segments Performed in 4Q17

    How Novartis Fared in 4Q17

  • What Analysts Expect for AstraZeneca Going Forward
    Market Realistlast month

    What Analysts Expect for AstraZeneca Going Forward

    What's Driving AstraZeneca’s Valuation in March 2018?

  • Why Investors Should Monitor Geopolitical Risks
    Market Realist2 months ago

    Why Investors Should Monitor Geopolitical Risks

    Localized geopolitical risks like the tension in the Middle East are unlikely to cause substantial damage to the markets in the long run, though they could bolster oil prices in the short term. The tension in the Korean Peninsula could be the biggest danger to market stability in the long run. As long as the balance is maintained between US interests and North Korea’s ambitions, the status quo is likely to prevail.

  • Valeant Pharmaceuticals on the Street: Analyst Ratings This February
    Market Realist2 months ago

    Valeant Pharmaceuticals on the Street: Analyst Ratings This February

    Valeant Pharmaceuticals (VRX) is a specialty pharmaceutical company involved in the development, manufacture, and marketing of branded, generic, branded generic as well as over the counter products. Of the seven analysts covering Valeant Pharmaceuticals in February 2018, two analysts have given the stock a “buy” or higher rating. Three analysts have given it a “hold” rating, and two analysts have given the stock a “sell” rating.

  • What’s behind the Stock Market Fall?
    Market Realist2 months ago

    What’s behind the Stock Market Fall?

    What Triggered the Stock Market Panic This Month? The last two trading sessions on February 2 and 5 have left many investors worried about assets in the bond (BND) and stock markets. The sell-off in the stock market began after the US employment report was published on Friday, February 2.

  • AstraZeneca: Analyst Ratings and Recommendations
    Market Realist3 months ago

    AstraZeneca: Analyst Ratings and Recommendations

    As we saw earlier, Wall Street analysts are estimating that AstraZeneca (AZN) will report EPS (earnings per share) of $0.47 on revenues of $5.4 billion in 4Q17, a 2.5% decline compared to $5.6 billion in 4Q16. AstraZeneca stock has risen 32% over the last 12 months. Analysts’ estimates show that the stock has a potential to return 8.6% over the next 12 months.

  • Meningitis Vaccines Portfolio Could Boost GSK’s Revenues in 2018
    Market Realist3 months ago

    Meningitis Vaccines Portfolio Could Boost GSK’s Revenues in 2018

    In 3Q17, GlaxoSmithKline (GSK) reported revenues close to 298 million pounds from the sale of its meningitis vaccines, which is year-over-year (or YoY) growth of 31% on a reported basis and 25% on a constant exchange rate (or CER) basis. The company’s meningitis vaccines portfolio witnessed sales worth 143 million pounds in the US market in 3Q17, which is YoY growth of 44% on a reported basis and 36% on a CER basis. GlaxoSmithKline earned revenues close to 103 million pounds from the sale of meningitis vaccines in Europe in 3Q17, which is a YoY rise of 34% on a reported basis and 30% on a CER basis.

  • GlaxoSmithKline Is Focused on Maintaining Leadership in This Segment
    Market Realist3 months ago

    GlaxoSmithKline Is Focused on Maintaining Leadership in This Segment

    To maintain its leadership in the chronic obstructive pulmonary disease (or COPD) segment, GlaxoSmithKline (GSK) has focused on shifting patients away from LAMA monotherapy to its LAMA/LABA bronchodilators, Anoro and Incruse. The company also expects to see COPD patients who are at higher risk of exacerbations to shift from open triple therapy to closed triple therapy such as the recently launched Trelegy Ellipta.

  • How Is Novartis’s Cosentyx Positioned for 2018?
    Market Realist3 months ago

    How Is Novartis’s Cosentyx Positioned for 2018?

    How Novartis Is Positioned for 2018

  • Approval of Alecensa in Europe Could Boost Roche’s Revenue Growth
    Market Realist3 months ago

    Approval of Alecensa in Europe Could Boost Roche’s Revenue Growth

    What to Expect from Roche in 2018

  • TEVA Stock Price Rises on Generic Launch of Viread
    Market Realist3 months ago

    TEVA Stock Price Rises on Generic Launch of Viread

    Key Updates from Teva Pharmaceuticals at the Start of 2018

  • What to Expect from Roche’s Tecentriq and Avastin in 2018
    Market Realist3 months ago

    What to Expect from Roche’s Tecentriq and Avastin in 2018

    What to Expect from Roche in 2018

  • Market Realist4 months ago

    How Did Novo Nordisk’s Modern Insulin Segment Perform in 3Q17?

    In 3Q17, Novo Nordisk’s (NVO) NovoRapid reported revenues of 5.0 billion Danish krone (or DKK), which reflected ~9% growth on year-over-year (or YoY) basis.

  • International Markets Beat US in 2017: 3 Best Country ETFs
    Zacks4 months ago

    International Markets Beat US in 2017: 3 Best Country ETFs

    While the U.S. stock market is in the midst of its second-longest bull run in history, the real encouragement came from the international stock market.

  • Best Index Funds for 2018
    Motley Fool5 months ago

    Best Index Funds for 2018

    Here are some of the best passively managed funds you can add to your portfolio.

  • 4 International ETFs Worth Buying at New Highs
    Zacks5 months ago

    4 International ETFs Worth Buying at New Highs

    The global stock market has climbed every single month this year, for the first time in the 30-year history of the MSCI AC World Index.

  • Market Realist5 months ago

    How Novartis’s Cosentyx Is Positioned after 3Q17

    In 3Q17, Novartis’s Cosentyx generated revenues of $556 million, which reflected a whopping 85% growth YoY (year-over-year) and ~13% growth QoQ.

  • Vanguard, genocide, and the $18 million campaign to get you to vote
    Yahoo Finance6 months ago

    Vanguard, genocide, and the $18 million campaign to get you to vote

    Why is Vanguard voting against a shareholder measure on its proxy ballot that moves to stop investing in companies that "substantially contribute" to genocide?

  • Market Realist7 months ago

    An Update on Novartis’s Tafinlar and Mekinist post 1H17

    In 1H17, Novartis's (NVS) Tafinlar & Mekinist reported revenues of around $403 million, which reflected ~25% growth on a year-over-year (or YoY) basis.

  • Morningstar7 months ago

    One of the Most Diversified Foreign-Stock Funds Available

    Vanguard Total International Stock ETF provides investors with a heavily diversified portfolio at a rock-bottom fee.

  • World ETF (VEU) Hits New 52-Week High
    Zacks8 months ago

    World ETF (VEU) Hits New 52-Week High

    This world ETF hit a new 52-week high. Are more gains in store for this ETF?